evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Dornase alfa vs alternate days

Mean relative percentage in quality of life score at 3 months · children with cystic fibrosis

Dornase alfa daily showed no clear difference in mean relative percentage in quality of life score at 3 months compared with alternate days (low certainty).

1 finding from 1 review

Dornase alfa vs hypertonic saline

FEV1 · children with cystic fibrosis

Dornase alfa may leads to higher mean relative percentage in FEV1 (L) at 3 months compared with hypertonic saline (low certainty).

1 finding from 1 review

Dornase alfa vs hypertonic saline

Mean relative percentage in FVC (L) at 3 months · children with cystic fibrosis

Dornase alfa showed no clear difference in mean relative percentage in FVC (L) at 3 months compared with hypertonic saline (low certainty).

1 finding from 1 review

Dornase alfa vs hypertonic saline

Mean relative percentage in quality of life score at 3 months · children with cystic fibrosis

Dornase alfa showed no clear difference in mean relative percentage in quality of life score at 3 months compared with hypertonic saline (low certainty).

1 finding from 1 review

Dornase alfa vs mannitol

FEV1 · children with cystic fibrosis

Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa vs mannitol

FVC · children with cystic fibrosis

Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa vs mannitol

QoL · children with cystic fibrosis

Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa vs mannitol

Exacerbations · children with cystic fibrosis

Dornase alfa showed no clear difference in number of people experiencing exacerbations ‐ at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa vs dornase alfa and mannitol

Exacerbations · children with cystic fibrosis

Dornase alfa showed no clear difference in number of people experiencing exacerbations at 3 months compared with dornase alfa and mannitol (low certainty).

1 finding from 1 review

Dornase alfa vs placebo or no dornase alfa treatment

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

Dornase alfa leads to higher relative mean percentage change in FVC (% predicted) at 6 months compared with placebo or no dornase alfa treatment (high certainty).

1 finding from 1 review

Dornase alfa vs placebo or no dornase alfa treatment

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

Dornase alfa showed no clear difference in change in quality of life ‐ CFQ‐R respiratory at 1 month compared with placebo or no dornase alfa treatment (low certainty).

2 findings from 1 review

Dornase alfa vs placebo or no dornase alfa treatment

Exacerbations · adults and children with cystic fibrosis

Dornase alfa probably leads to lower number of people experiencing exacerbations at up to 2 years compared with placebo or no dornase alfa treatment (moderate certainty).

1 finding from 1 review